Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: February 4, 2023

Details for Patent: 7,511,041

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,511,041 protect, and when does it expire?

Patent 7,511,041 protects ALIQOPA and is included in one NDA.

This patent has fifty patent family members in thirty-two countries.

Summary for Patent: 7,511,041

Title:	Fused azole-pyrimidine derivatives
Abstract:	The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-.gamma. inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-.gamma. activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.
Inventor(s):	Shimada; Mitsuyuki (Nara, JP), Murata; Toshiki (Nara, JP), Fuchikami; Kinji (Tokyo, JP), Tsujishita; Hideki (Kyoto, JP), Omori; Naoki (Hyogo, JP), Kato; Issei (Nara, JP), Miura; Mami (Nara, JP), Urbahns; Klaus (Lund, SE), Gantner; Florian (Constance, DE), Bacon; Kevin (San Diego, CA)
Assignee:	Bayer Pharmaceuticals Corporation (West Haven, CT)
Application Number:	10/527,376
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 7,511,041

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	ALIQOPA	copanlisib dihydrochloride	POWDER;INTRAVENOUS	209936-001	Sep 14, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y	Y			See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 7,511,041

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	02021861	Sep 30, 2002

PCT Information
PCT Filed	September 18, 2003	PCT Application Number:	PCT/EP03/10377
PCT Publication Date:	April 08, 2004	PCT Publication Number:	WO2004/029055

International Family Members for US Patent 7,511,041

Subscribe to access the full database, or Sign up for a Free Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	041426	See Plans and Pricing
Argentina	072458	See Plans and Pricing
Austria	411996	See Plans and Pricing
Austria	511510	See Plans and Pricing
Australia	2003293310	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck

Johnson and Johnson

Dow

Moodys

McKinsey

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.